Healthcare shares were generally mixed in pre-market trade on Wednesday.
In healthcare stocks news, St. Jude Medical ( STJ ), a global medical device company, reports that the first patient implants have occurred in the Portico Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO trial).
The trial is evaluating the Portico Transcatheter Aortic Valve System, the first aortic heart valve that is repositionable until fully deployed. Data collected from the trial will be used to support approval of the Portico Transcatheter Aortic Valve Replacement System by the U.S. Food and Drug Administration (FDA).
Shares of STJ closed the day's regular session at $64.39 and are unmoved after-hours.
And, RXi Pharmaceuticals Corporation ( RXII ), which made its market debut in February, said its Q1 net loss narrowed though revenue fell.
The net loss attributable to common shareholders was $4 million, or $0.32 a share from $17.9, or $2.76 a share a year earlier. Analysts were expecting $0.31, if comparable.
Finally, Eagle Pharmaceuticals ( EGRX ) reported financial results for Q2, or the quarter ended March 31, 2014, with a deeper-than-expected loss while revenue topped analysts' expectations.
The specialty pharmaceutical company reported Q2 net loss of $3.2 million or $0.36 per share, compared with the prior-year period's $5.6 million or $1.86 per share. Revenue was $5 million, up 2.5% from $2.5 million in the same quarter last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.